- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04194827
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA)
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Since the introduction of biologics in rheumatology, as well as treat-to-target (measuring disease activity and adapting treatment accordingly) the prognosis of patients has improved substantially. Obviously, patient burden due to self-injection or infusion, the risk of adverse events and costs demand responsible use of these agents. Multiple studies have shown that a large proportion of patients with rheumatoid arthritis with stable low disease activity can taper their dose or stop without relapse of disease activity. This can be done by using disease activity guided tapering. Drawbacks, however, include increased risk for short lived flares, the effort of slowly and carefully tapering, and somewhat more risk of radiographic damage due to higher mean disease activity. As most biologics are characterized by wide variation in pharmacokinetics between patients, therapeutic drug monitoring (TDM), i.e. dose based on serum trough concentration, might be an attractive approach to lower the dose quickly while remaining clinical efficacy. Although some data suggest that the minimal effective concentration varies between patients, we demonstrated in an earlier study that serum adalimumab concentration of 5 mg/L is enough for initial response to adalimumab. In the first phase of treatment, drug concentration must be high enough to control immunogenicity. To control disease activity after 28 weeks, lower concentrations than 5 mg/L are probably sufficient. Since around 70% of the patients have an adalimumab concentration above 5 mg/l, we assume that dose reduction to achieve these lower targets (for example direct doubling of interval in patients with levels > 10 mg/L) will result in the lowest effective drug dose. Our study group illustrated in 2018 that dose reduction by extending the dosing interval with 50% is non inferior to continuation of standard dose in patients with adalimumab levels > 8mg/L. In other words, measuring drug concentrations can help clinicians to select overexposed patients to reduce the dose of adalimumab without adversely affecting clinical efficiency. We posit that therapeutic drug monitoring can attribute to a more efficient dose reduction strategy. Since steady state drug concentrations are achieved within 16 weeks of treatment, we expect that the dose can be reduced from this point. This is earlier in treatment compared to the strategy using disease activity alone, namely after 6 months of treatment. Conceptually, such a test can improve disease activity guided dose reduction in two ways: 1) flaring caused by empirical tapering (i.e. through trial and error) below the minimal effective concentration would be avoided, and 2) patients can be directly given their minimum effective dose instead of empirical tapering, thereby saving time and drugs. Our aim is to investigate whether the use of drug levels can attribute to a more efficient dose reduction strategy of adalimumab in patients with RA. In this study we will compare costs and clinical efficiency of two dose reduction strategies: a strategy using drug concentration versus a strategy using disease activity scores. We expect that direct medical costs will be lower in the 'drug concentration guided' strategy because: 1) overexposed patient can reduce the dose more timely and, 2) adalimumab dose can be further reduced after 6 months of treatment since we posit that adalimumab concentration of 2 mg/L is sufficient to control disease.
In this multi-centre, randomised, open-label trail we will evaluate whether dose reduction of adalimumab using drug concentration can reduce medical costs compared to a strategy using disease activity scores. Furthermore we will evaluate the clinical efficiency of these two strategies.
Patients with a good or moderate EULAR response to adalimumab will be randomised to adalimumab dose reduction strategy using drug concentration or disease activity scores. Patients in the 'drug concentration guided' group will reduce adalimumab dose by prolonging the dose-interval using TDM algorithm (a new developed algorithm is used to determine the interval prolongation for each patient). The dose reduction will start at week 16 if trough drug level is higher than 5mg/L, aiming a drug level of 5mg/L in week 16 until 28 and a drug level of 2mg/L from week 28 until week 52. In the initial 16 weeks patients are treated with adalimumab at registered dose of 40mg every other week.
Patients in the 'disease activity guided' group will reduce adalimumab dose at week 28 if DAS28-CRP is lower than 2.9. This dose reduction will be attained by extending the dosing interval to every 3 weeks in weeks 28 until 40 and to every 4 weeks from week 40 until week 52.
Patients who successfully prolonged the dose interval to 40 mg every 4 weeks in the 'disease activity guided' group and patients who successfully prolonged their dose-interval and achieve a serum concentration of 2.0 mg/L in the 'drug concentration guided' group will be approached to participate to the extension phase (week 52-80). After informed consent is obtained patients will discontinue adalimumab and they will be followed up to week 80.
Data regarding disease status, functioning, adalimumab serum concentrations, anti-drug antibodies and medical costs will be collected during this study.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Femke Hooijberg
- Phone Number: 0031202421633
- Email: f.hooijberg@reade.nl
Study Contact Backup
- Name: Sadaf Atiqi, MD
- Phone Number: 0031-202421641
- Email: s.atiqi@reade.nl
Study Locations
-
-
Noord Holland
-
Amsterdam, Noord Holland, Netherlands, 1056AB
- Recruiting
- Reade Rheumatology Research Institute
-
Contact:
- Femke Hooijberg
- Phone Number: 0031-202421633
- Email: f.hooijberg@reade.nl
-
Contact:
- Sadaf Atiqi, MD
- Phone Number: 0031-202421641
- Email: s.atiqi@reade.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010 criteria;
- Starting adalimumab as the first biological therapy
- Who has agreed to participate (written informed consent);
- Age 18 years or older.
Exclusion Criteria:
- Scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation;
- Life expectancy shorter than follow-up period of the study;
- Other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Concentration guided dose reducion
Dose reduction of adalimumab will be based on adalimumab through concentration after 16 weeks of treatment with adalimumab.
|
Dose reduction based on adalimumab serum trough concentration
Adalimumab
|
Active Comparator: Disease activity quided dose reduction
Dose reduction of adalimumab will be based on disease activity after 28 weeks of treatment with adalimumab
|
Adalimumab
Dose reduction based on adalimumab diseas activity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medical costs
Time Frame: 52 weeks
|
Direct medical costs associated with adalimumab dose reduction using drug concentration versus using disease activity scores
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean time weighted DAS28-CRP
Time Frame: at 16, 28, 52 and 80 weeks
|
Difference in mean time weighted DAS28-CRP
|
at 16, 28, 52 and 80 weeks
|
Direct medical costs
Time Frame: at week 28 and week 80
|
Direct medical costs (medication, visits, cost TDM testing) at the separate time points
|
at week 28 and week 80
|
Indirect medical costs
Time Frame: at 28, 52 and 80 weeks
|
Costs due to RA-related work absenteeism and presentism for patients with paid jobs and days of inactivity for patients without a paid job.
Indirect costs will be estimated by three-monthly questionnaires, monitoring these items in the previous month (based on the SF-HLQ).
|
at 28, 52 and 80 weeks
|
Patients with DAS28-CRP<2.9
Time Frame: at 52 and 80 weeks
|
Percentage of patients with DAS28-CRP<2.9
|
at 52 and 80 weeks
|
Number of flares
Time Frame: at 52 and 80 weeks
|
at 52 and 80 weeks
|
|
Number of dose-interval shortenings
Time Frame: at 52 and 80 weeks
|
at 52 and 80 weeks
|
|
Drug levels
Time Frame: at 4,16, 28, 40, 52 and 80 weeks
|
The difference in drug levels between the measured drug level and the predicted drug level with the (newly developed) algorithm at different timepoints
|
at 4,16, 28, 40, 52 and 80 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Gertjan Wolbink, PhD, Reade Rheumatology Research Institute
Publications and helpful links
General Publications
- l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.
- Chen DY, Chen YM, Hsieh TY, Hung WT, Hsieh CW, Chen HH, Tang KT, Lan JL. Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology (Oxford). 2016 Jan;55(1):143-8. doi: 10.1093/rheumatology/kev298. Epub 2015 Aug 31.
- Kievit W, van Herwaarden N, van den Hoogen FH, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, van der Maas A, den Broeder AA. Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Ann Rheum Dis. 2016 Nov;75(11):1939-1944. doi: 10.1136/annrheumdis-2015-208317. Epub 2016 Jan 13.
- Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, Wolbink G. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015 Mar;74(3):513-8. doi: 10.1136/annrheumdis-2013-204172. Epub 2013 Dec 10.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADDORA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on Adalimumab serum trough concentration
-
Reade Rheumatology Research InstituteZonMw: The Netherlands Organisation for Health Research and Development; Sint...Active, not recruiting
-
Pontificia Universidad Catolica de ChileHospital Dr Sotero del RioUnknownDry Eye | Keratoconjunctivitis Sicca | Lacrimal Apparatus Diseases | Conjunctival Diseases | Keratitis | Corneal Diseases | Sjogren's SyndromeChile
-
Karolinska University HospitalCompletedThe Value of Procalcitonin in Patients With Suspected CandidemiaSweden
-
Assistance Publique - Hôpitaux de ParisEuropean Georges Pompidou Hospital; Clinical haematology and BMT unit,Necker... and other collaboratorsCompleted
-
University Hospital, GhentKU LeuvenCompleted
-
University of LeipzigCompletedNon-cardiac DiseaseGermany
-
Recep Tayyip Erdogan University Training and Research...CompletedAnkylosing Spondylitis
-
Sheppard Pratt Health SystemStanley Medical Research InstituteCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
University of Sao Paulo General HospitalCompleted
-
Pinyo RattanaumpawanUnknownMethicillin-Resistant Staphylococcus AureusThailand